Clinical trials
Cancer of Gastrointestinal Tract clinical trials
Below are recruiting cancer of gastrointestinal tract clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT07412379Recruiting
Predicting recovery after cancer surgery for older adults
This study looks at how older adults (65+) with digestive tract cancers respond to surgery aimed at a cure. Researchers want to see what factors affect recovery and quality of life after the operation.
BogotáAges 65 years+ - NCT07586813RecruitingPhase 2
Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
BeijingAges 18 years+ - NCT06282016Recruiting
Risk factors for neuroendocrine tumors in Bavaria
This study looks at medical records from people in Bavaria to find out what might increase the risk of developing neuroendocrine neoplasms (a rare type of tumor). By reviewing routine health data, researchers hope to discover early signs or risk factors that could help with future detection and care.
Nuremberg, BavariaAges Any age - NCT07769892Recruiting
Blood and stool test for digestive tract cancer screening
This study is testing a new way to screen for cancers of the digestive tract using a simple blood and stool test. It is for people who are already scheduled to have a digestive tract endoscopy, and it may help find cancers earlier without extra invasive procedures.
Zhaoqing, GuangdongAges 45–74 - NCT06764095RecruitingPhase 4
Drug combo before bladder or ureter surgery for advanced cancer
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Rochester, MinnesotaAges 18 years+ - NCT07219537Recruiting
Imaging the lower gut with a new capsule
This trial tests a new type of camera capsule that takes pictures of the lower part of your digestive tract. It may be an option for people who are healthy or have Lynch Syndrome and have had a recent normal colonoscopy.
Boston, MassachusettsAges 18–75 - NCT06104241RecruitingEarly Phase 1
Cell therapy for advanced digestive cancers
This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.
Xuzhou, JangSuAges 18–70 - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT07786766RecruitingPhase 2
Pemigatinib plus immunotherapy for FGFR2-positive bile duct cancer
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
BeijingAges 18–80 - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT07106424Recruiting
Early screening study for multiple gastrointestinal tumors
This study is looking for people aged 40-75 who have never had cancer to participate in early screening for gastrointestinal tumors. The goal is to find cancers early when they are easier to treat.
Jinan, ShandongAges 40–75 - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT06081647Recruiting
Testing a new airway device for endoscopy
This trial tests a special mouth-and-throat device designed to help you breathe easier during a routine endoscopy or colonoscopy. If you are a generally healthy adult scheduled for one of these procedures, you may be able to join.
Nanjing, JiangsuAges 18–60 - NCT06749730RecruitingPhase 2
Study of four drugs for advanced bile duct cancer
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
ZhengzhouAges 18–80 - NCT07175155Recruiting
Breathing device and oxygen for endoscopy in severe obesity
This study tests a special breathing device (a tube placed in the throat) combined with high-flow oxygen through the nose during sedation for endoscopy in people with severe obesity. It aims to see if this combination helps keep oxygen levels stable and makes the procedure safer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06478030Recruiting
Combined screening for stomach and bowel cancer
This study is testing a combined screening method for finding cancer in the stomach and intestines at an early stage. It is for people in Zhejiang Province who are willing to be screened and followed over time.
Jinhua, ZhejiangAges 40–74 - NCT06796764Recruiting
Breathing tube safety during endoscopy in people with obesity
This trial tests a special breathing tube to see if it can prevent low oxygen levels during sedated endoscopy in people with obesity. If you are scheduled for both an upper endoscopy and colonoscopy, this study may help make the procedure safer.
Hangzhou, ZhejiangAges 18–70 - NCT07780838RecruitingPhase 2
Combination therapy for advanced bile duct cancer with an FGFR2 change
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
Columbus, OhioAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07494864Recruiting
Urinary tract health and microbiome study
This study looks at how bacteria and the immune system affect the lower urinary tract. It includes healthy volunteers and people with various urinary conditions, like infections or bladder pain.
Zurich, Canton of ZurichAges 18 years+
Hear when a new Cancer of Gastrointestinal Tract trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer of gastrointestinal tract?
- Yes. Clin2 currently lists 69 recruiting cancer of gastrointestinal tract studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer of gastrointestinal tract trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer of gastrointestinal tract trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.